The European financial advisory landscape for Healthcare Technology (HealthTech) and Medical Technology (MedTech) is undergoing a structural realignment, transitionally termed the Great Rationalisation. This shift represents a departure from the liquidity-fueled, growth-at-all-costs environment of the early 2020s toward a highly disciplined, metrics-centric climate. Enterprise valuation in this environment is no longer determined by raw revenue expansion; instead, it is dicta